Clinical Trials Directory

Trials / Completed

CompletedNCT01570660

Phielix et al.: Hepatic Fat Content and Adipokines

Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
24 (actual)
Sponsor
German Diabetes Center · Academic / Other
Sex
All
Age
45 Years – 65 Years
Healthy volunteers
Accepted

Summary

Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.

Conditions

Interventions

TypeNameDescription
DRUGPioglitazone12 weeks of pioglitazone treatment

Timeline

Start date
2002-02-01
Primary completion
2012-03-01
Completion
2012-03-01
First posted
2012-04-04
Last updated
2012-04-04

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT01570660. Inclusion in this directory is not an endorsement.